V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2) (pTyr1139) antibody

Details for Product No. ABIN649824
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms Neu, HER2, HER-2, c-neu, Erbb-2, c-erbB2, mKIAA3023, CD340, HER-2/neu, MLN 19, NEU, NGL, TKR1
Epitope
pTyr1139
(57), (45), (44), (41), (38), (31), (22), (21), (15), (10), (9), (8), (8), (6), (6), (5), (4), (4), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human
(679), (294), (224), (92), (60), (48), (37), (24), (7), (1), (1), (1), (1), (1)
Host
Rabbit
(511), (179), (16), (11), (4), (1), (1)
Clonality
Monoclonal
Conjugate
Un-conjugated
(25), (11), (10), (10), (10), (10), (10), (10), (10), (10), (10)
Application
Western Blotting (WB)
(432), (199), (199), (185), (150), (100), (100), (49), (38), (33), (25), (10), (5), (5), (2), (2), (1), (1), (1), (1), (1), (1), (1)
Pubmed 5 references available
Catalog no. ABIN649824
Quantity 100 µL
Price
507.14 $   Plus shipping costs $45.00
Options
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Specificity A synthetic peptide corresponding to residues surrounding tyrosine 1139 of human HER2 / ErbB2 was used as an immunogen.
Alternative Name HER2 (ErbB2)
Background HER2 (ErbB2, epidermal growth factor receptor 2) is one of the four members of the ErbB receptor family of transmembrane receptor-like tyrosine kinases (1). The kinase activity of HER2 can be activated without ligand if it is overexpressed, and by association with other HER proteins (2). Overexpression of HER2 is detected in almost 40% of human breast cancers (3). Therefore, HER2 is considered one of the major targets for the treatment of breast cancer and other carcinomas. Binding of c-Cbl ubiquitin ligase to Tyr1112 of HER2 leads to poly-ubiquitination of HER2 and enhances its degradation (4). Similar to other growth factors, HER2 exhibits intrinsic protein tyrosine kinase activity and undergoes autophosphorylation (Y1023, Y1248, Y1139, and Y1222). A phosphorylation at tyrosine 1139 has been identified to induce the binding of Src to HER2, leading to HER2 activation of Stat3 alpha (5).
Synonyms: ERBB2, HER2, NEU, NGL, Receptor tyrosine-protein kinase erbB-2, p185erbB2,C-erbB-2,NEU proto-oncogene,Tyrosine kinase-type cell surface receptor HER2,MLN 19
Molecular Weight 185 kDA
Gene ID 2064
UniProt P04626
Research Area Ubiquitin-related antibodies, Phospho-specific antibodies, Cell Signaling, Protein Modifications, Cell Structure, Signaling, Chromatin
Application Notes The suggested dilution is: WB: = 1:500-1000
Comment

Background: HER2 (ErbB2, epidermal growth factor receptor 2) is one of the four members of the ErbB receptor family of transmembrane receptor-like tyrosine kinases (1). The kinase activity of HER2 can be activated without ligand if it is overexpressed, and by association with other HER proteins (2). Overexpression of HER2 is detected in almost 40% of human breast cancers (3). Therefore, HER2 is considered one of the major targets for the treatment of breast cancer and other carcinomas. Binding of c-Cbl ubiquitin ligase to Tyr1112 of HER2 leads to poly-ubiquitination of HER2 and enhances its degradation (4). Similar to other growth factors, HER2 exhibits intrinsic protein tyrosine kinase activity and undergoes autophosphorylation (Y1023, Y1248, Y1139, and Y1222). A phosphorylation at tyrosine 1139 has been identified to induce the binding of Src to HER2, leading to HER2 activation of Stat3 alpha (5).

Restrictions For Research Use only
Format Liquid
Buffer 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Preservative Sodium azide
Storage -20 °C
Storage Comment HER2 (ErbB2) Antibody Phospho (pY1139) can be stored at -20°C for up to 12 months from time of receipt.
Expiry Date 12 months
Background publications Qian, LeVea, Freeman et al.: "Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, Issue 4, pp. 1500-4, 1994 (PubMed).

Muthuswamy, Gilman, Brugge: "Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers." in: Molecular and cellular biology, Vol. 19, Issue 10, pp. 6845-57, 2000 (PubMed).

Klapper, Waterman, Sela et al.: "Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2." in: Cancer research, Vol. 60, Issue 13, pp. 3384-8, 2000 (PubMed).

Dittadi, Gion: "More about: prognostic importance of low c-erbB2 expression in breast tumors." in: Journal of the National Cancer Institute, Vol. 92, Issue 17, pp. 1443-4, 2000 (PubMed).

Ren, Schaefer: "ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner." in: The Journal of biological chemistry, Vol. 277, Issue 41, pp. 38486-93, 2002 (PubMed).

Hosts (511), (179), (16), (11), (4), (1), (1)
Reactivities (679), (294), (224), (92), (60), (48), (37), (24), (7), (1), (1), (1), (1), (1)
Applications (432), (199), (199), (185), (150), (100), (100), (49), (38), (33), (25), (10), (5), (5), (2), (2), (1), (1), (1), (1), (1), (1), (1)
Conjugates (25), (11), (10), (10), (10), (10), (10), (10), (10), (10), (10)
Epitopes (57), (45), (44), (41), (38), (31), (22), (21), (15), (10), (9), (8), (8), (6), (6), (5), (4), (4), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top